PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatment, a single infusion of PA3-17 injection will be administered. Blood samples will be collected from the subjects before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations. In addition to the baseline period, the treatment phase will involve efficacy assessments at 4 weeks, 2 months, 3 months, and every 3 months thereafter, up to 24 months post-cell infusion. Tumor assessments will continue until disease progression (PD), initiation of new antitumor treatment, death, unacceptable toxicity, investigator decision, or subject's voluntary withdrawal, whichever occurs first.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Przewidywana długość życia co najmniej 3 miesiące.
- •Potwierdzona diagnoza białaczki lub chłoniaka limfoblastycznego T, który nawrócił lub nie reaguje na leczenie.
- •Komórki nowotworowe wykazują obecność znacznika CD7.
- •Narządy takie jak wątroba, nerki, serce i płuca funkcjonują prawidłowo.
- •Zdolność do zrozumienia badania i wyrażenia zgody na udział.
✗ Disqualifies
- •Aktywne lub niekontrolowane choroby autoimmunologiczne.
- •Choroba przeszczep przeciwko gospodarzowi (GvHD).
- •Inne nowotwory w ciągu ostatnich 5 lat (z pewnymi wyjątkami).
- •Pozytywne wyniki testów na zapalenie wątroby typu B, C, kiłę.
- •Ciężka choroba serca.
- •Ciężka choroba psychiczna.
- •Ciąża lub karmienie piersią; plany dotyczące poczęcia dziecka w ciągu 2 lat po leczeniu.
- •Wcześniejsze leczenie komórkami CAR-T lub innymi zmodyfikowanymi komórkami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, China
Peking University People's Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, China
Facility Name: Guangdong Provincial People's Hospital
Guangzhou, China
The First Hospital of Harbin
Harbin, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Jiangsu Province Hospital
Nanjing, China
The First Affiliated Hospital of Soochow University
Suzhou, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Tongji Hospital, Tongji University
Shanghai, China
West China Hospital, Sichuan University (WCHSU)
Chengdu, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Trial contact
Xiaojun Huang, MD
Mingzhi Zhang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.